Vetivex 6 (Glucose 5% w/v Intravenous Infusion BP (Vet))

البلد: المملكة المتحدة

اللغة: الإنجليزية

المصدر: VMD (Veterinary Medicines Directorate)

العنصر النشط:

Glucose

متاح من:

Dechra Limited

ATC رمز:

QB05BA03

INN (الاسم الدولي):

Glucose

الشكل الصيدلاني:

Solution for infusion

نوع الوصفة الطبية :

POM-V - Prescription Only Medicine – Veterinarian

المجموعة العلاجية:

Cats, Cattle, Dogs, Horses

المجال العلاجي:

Replacement Agent

الوضع إذن:

Expired

تاريخ الترخيص:

1998-10-20

خصائص المنتج

Revised: March 2011
Amended pages
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VETIVEX 6 (Glucose 5 % w/v Intravenous Infusion BP (Vet))
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Glucose monohydrate
5.5 % w/v
(equivalent to anhydrous glucose 5.0 % w/v)
Each one litre provides approximately 200 kcal.
3.
PHARMACEUTICAL FORM
A clear, colourless solution for infusion.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, calves, horses, dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
This product is administered by intravenous infusion for the treatment
of
dehydration (in the absence of shock) in cattle, calves, horses, dogs
and cats. It
is used to replace water when it cannot be taken or retained orally.
Glucose infusions are used to correct hypernatraemia (by replacing
lost water)
and hyperkalaemia (through the promotion of insulin production which
in turn
causes potassium to move from plasma into cells). It is not a
significant calorie
source but can provide transient improvement of hypoglycaemia.
4.3
CONTRAINDICATIONS
This product should not be administered to hyperglycaemic animals.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
This product should be used with care in diabetic patients.
A risk of thrombosis with intravenous infusion should be considered.
Revised: March 2011
Amended pages
Page 2 of 4
This product should not be administered at rate in excess of
10 ml/kg/hour, otherwise glycosuria and osmotic diuresis may result.
Furthermore, severe or long-standing hypernatraemia should be
corrected
gradually.
ii.
Special precautions to be taken by the person administering the
medicinal
product to animals
No special precautions required.
iii.
Other precautions
None required.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Monitor fluid output and blood glucose.
4.7
USE DURING PREGNANCY AND LACTATION OR LAY
Use under veterinary supervision.
4.8
INTERACTION WITH OTHER ME